In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 241 to 250 of 303

TitleTypeExpected publication date
Seladelpar for previously treated primary biliary cholangitis ID6429Technology appraisal guidance
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]Technology appraisal guidanceTBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidanceTBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidanceTBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Technology appraisal guidanceTBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All